Seegene | GenomeWeb

Seegene

The partnership marks the first step in the company's plan to develop 100 new molecular diagnostics within the next two years.

Seegene will use its proprietary assay development technologies to create highly multiplexed tests for the Hologic Fusion platform. 

The service — which Seegene plans to launch next year — boasts the specificity of fluorescently tagged probes at the cost of intercalating dyes.

Partnering with Biodist Group, the South Korean molecular diagnostics firm is looking to move into non-human applications such as food safety testing.

The worldwide collaboration agreement is for co-development of multiplex real-time PCR reagents for the BD Max molecular diagnostics platform.

Seegene will develop a menu of multiplex assay panels, initally in the area of infectious disease, for Qiagen's QIAsymphony RGQ molecular diagnostics platform.

The company has also received approvals for various molecular diagnostics in the US and Canada in recent months.

The South Korean molecular diagnostics firm plans to grow its global market presence and pursue FDA approval for its products from Seegene Technologies, its new base in California.

The molecular diagnostic test identifies influenza virus A subtypes H1 and H3, influenza B, and human respiratory syncytial viruses A and B.

The test uses the company's TOCE primer technology for multiplexed real-time PCR and is the first product Seegene has taken through the FDA.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.